{"id":781104,"date":"2023-08-30T16:05:23","date_gmt":"2023-08-30T20:05:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/"},"modified":"2023-08-30T16:05:23","modified_gmt":"2023-08-30T20:05:23","slug":"longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/","title":{"rendered":"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings<\/b><\/p>\n<p>LA JOLLA, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.longboardpharma.com&amp;esheet=53546776&amp;newsitemid=20230830992609&amp;lan=en-US&amp;anchor=Longboard+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=4a821593a01d12a2defca65ea6e8b0a8\">Longboard Pharmaceuticals, Inc.<\/a> (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting.<\/p>\n<p><b>Presentation Details:<\/b><\/p>\n<p><b>IEC <\/b><b>September 2-6, 2023 \u2013 Dublin, Ireland<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Title:<\/b><i>A Phase 1 Clinical Study Shows Robust LP352 CSF Exposures Supporting Dose Optimization for 5-HT2C Receptor Engagement<\/i><i> (#746)<br \/>\n<br \/><\/i><b>Details:<\/b><i> Digital poster<\/i><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Title:<\/b><i>The PACIFIC Study: A Phase 1b\/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies (#758)<br \/>\n<br \/><\/i><b>Oral Presentation Date\/Time:<\/b><i> September 5, 2:00 PM-2:30 PM GMT<\/i><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Title:<\/b><i>Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist (#754)<br \/>\n<br \/><\/i><b>Oral Presentation Date\/Time:<\/b><i> September 5, 2:00 PM-2:30 PM GMT<\/i><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Title:<\/b><i>Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist (#749)<br \/>\n<br \/><\/i><b>Oral Presentation Date\/Time:<\/b><i> September 5, 2:00 PM-2:30 PM GMT<\/p>\n<p>All posters will be available digitally throughout the duration of the conference<\/i><\/li>\n<\/ul>\n<p><b>ACCP <\/b><b>September 10-12, 2023 \u2013 Bellevue, WA<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Title:<\/b> A Phase 1 Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics, and QEEG Changes Reflecting Receptor Engagement (#060)<br \/>\n<br \/><b>Oral Presentation Date\/Time:<i \/><\/b><i>September 10, 5:00 PM-7:00 PM PT<\/i><\/li>\n<\/ul>\n<p><b>ABOUT LP352<\/b><\/p>\n<p>\nLP352 is an oral, centrally acting, 5-HT2C superagonist in development for the potential treatment of seizures associated with DEEs such as Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related epilepsies, CDKL5 deficiency disorder, and other epileptic disorders. LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures. LP352 has no detected activity at the 5-HT2B and 5-HT2A receptor subtypes. 5-HT2B and 5-HT2A receptor agonism have been associated with significant adverse side effects. LP352 has novel chemistry and attributes. It was designed to be more specific and selective for the 5-HT2C receptor subtype, giving it the potential to reduce seizures in patients with DEEs while overcoming the known or perceived safety limitations of available drugs in the 5-HT2 class. LP352 is currently being evaluated in a Ph 1b\/2a clinical trial (the PACIFIC Study) in participants with DEEs, with data expected around year-end 2023, as well as in additional supportive studies.<\/p>\n<p><b>ABOUT LONGBOARD PHARMACEUTICALS<\/b><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.longboardpharma.com%2F&amp;esheet=53546776&amp;newsitemid=20230830992609&amp;lan=en-US&amp;anchor=Longboard+Pharmaceuticals%2C+Inc.&amp;index=2&amp;md5=25c39d9d6216e28f79f5e6e75aee91ab\">Longboard Pharmaceuticals, Inc.<\/a> is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.longboardpharma.com%2Four-approach%2F%23pipeline&amp;esheet=53546776&amp;newsitemid=20230830992609&amp;lan=en-US&amp;anchor=product+candidates&amp;index=3&amp;md5=97d47182d7896b629b7153c5b3a0e7a0\">product candidates<\/a> designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard\u2019s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no detectable activity on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of Developmental and Epileptic Encephalopathies. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of multiple neurological diseases.<\/p>\n<p><b>FORWARD-LOOKING STATEMENTS<\/b><\/p>\n<p>\nCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard\u2019s participation in the upcoming meetings and Longboard\u2019s clinical and preclinical programs and product candidates, ability to develop product candidates and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard\u2019s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard\u2019s forward-looking statements are disclosed in Longboard\u2019s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard\u2019s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230830992609\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230830992609\/en\/<\/a><\/span><\/p>\n<p><b>CORPORATE CONTACT:<br \/>\n<\/b><br \/>Megan E. Knight<br \/>\n<br \/>Head of Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@longboardpharma.com\">IR@longboardpharma.com<br \/>\n<\/a><br \/>858.789.9283<\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230830992609\/en\/1878357\/3\/Longboard_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211;Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting. Presentation Details: IEC September 2-6, 2023 \u2013 Dublin, Ireland Title:A Phase 1 Clinical Study Shows Robust LP352 CSF Exposures Supporting Dose Optimization for 5-HT2C Receptor Engagement (#746) Details: Digital poster Title:The PACIFIC Study: A Phase 1b\/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies (#758) Oral Presentation Date\/Time: September 5, 2:00 PM-2:30 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781104","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211;Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting. Presentation Details: IEC September 2-6, 2023 \u2013 Dublin, Ireland Title:A Phase 1 Clinical Study Shows Robust LP352 CSF Exposures Supporting Dose Optimization for 5-HT2C Receptor Engagement (#746) Details: Digital poster Title:The PACIFIC Study: A Phase 1b\/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies (#758) Oral Presentation Date\/Time: September 5, 2:00 PM-2:30 &hellip; Continue reading &quot;Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T20:05:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings\",\"datePublished\":\"2023-08-30T20:05:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/\"},\"wordCount\":722,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/\",\"name\":\"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-08-30T20:05:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/","og_locale":"en_US","og_type":"article","og_title":"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings - Market Newsdesk","og_description":"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211;Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting. Presentation Details: IEC September 2-6, 2023 \u2013 Dublin, Ireland Title:A Phase 1 Clinical Study Shows Robust LP352 CSF Exposures Supporting Dose Optimization for 5-HT2C Receptor Engagement (#746) Details: Digital poster Title:The PACIFIC Study: A Phase 1b\/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies (#758) Oral Presentation Date\/Time: September 5, 2:00 PM-2:30 &hellip; Continue reading \"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T20:05:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings","datePublished":"2023-08-30T20:05:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/"},"wordCount":722,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/","name":"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-08-30T20:05:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230830992609r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-present-data-at-upcoming-medical-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781104"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781104\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}